Order results by:
| Issue | Title | |
| Vol 17, No 1 (2025) | Aggressive multiple sclerosis in the Republic of Bashkortostan | Abstract similar documents |
| K. Z. Bakhtiyarova, U. Sh. Kuzmina, O. V. Lyutov, I. D. Talipova, N. F. Akhmetgaleeva, T. R. Galiullin, M. A. Kutlubaev | ||
| "... of patients with aggressive MS, the progression rate was significantly higher than in the HAMS group. Six ..." | ||
| Vol 14, No 1 (2022) | Biological basis of aggressive behavior | Abstract similar documents |
| O. A. Makushkina, O. I. Gurina, V. A. Golenkova | ||
| "... the biological aspects of failure to control aggressive impulses. We analyze the role of serotonergic ..." | ||
| Vol 13, No 5 (2021) | Biological basis of aggressive behavior | Abstract similar documents |
| O. A. Makushkina, O. I. Gurina, V. A. Golenkova | ||
| "... manifestation. We discuss the inconsistency of modern concepts about the neurochemical nature of aggressive ..." | ||
| Vol 14, No 1S (2022): Спецвыпуск: рассеянный склероз | Results of a study of the quality of life in patients with highly active multiple sclerosis in Russia | Abstract similar documents |
| A. N. Boiko, K. Z. Bakhtiyarova, M. A. Sherman, Z. A. Goncharova, I. V. Smagina, T. I. Khaibullin, N. N. Babicheva, N. N. Spirina, I. A. Yampolskaya-Gosteva, I. A. Sokolova, I. V. Greshnova, V. E. Nikitenkova, I. G. Lukashevich, A. V. Inzhinova, N. A. Malkova, D. S. Korobko, O. V. Boyko, I. S. Lozovskaya | ||
| "... , the number of cases with highly active MS (HAMS) is increasing, i.e. cases of MS with two or more ..." | ||
| Vol 12, No 3 (2020) | Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis | Abstract similar documents |
| K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. V. Davydovskaya, M. N. Zakharova, N. A. Malkova, A. I. Nilov, S. A. Sivertseva, N. N. Spirin, N. A. Totolyan, F. A. Khabirov, M. V. Shumilina | ||
| "... (MS), especially for highly active MS (HAMS), in which there are ≥2 exacerbations and corresponding ..." | ||
| Vol 14, No 1 (2022) | Experience with cladribine tablets for highly active multiple sclerosis in real clinical practice | Abstract similar documents |
| S. V. Petrov, O. V. Boyko, A. N. Boyko | ||
| "... reconstitution of highly active multiple sclerosis (HAMS) in general clinical practice. Patients and methods. 34 ..." | ||
| Vol 16, No 5 (2024) | Efficacy and safety of cladribine tablets in multiple sclerosis in real-world clinical practice | Abstract similar documents |
| A. N. Peshkin, S. V. Kotov, G. T. Toniya, M. V. Sutormin, A. F. Eltayoury | ||
| "... (HAMS). According to the instructions for use, oral therapy with cladribine was administered in two ..." | ||
| Vol 12, No 5 (2020) | Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets | Abstract similar documents |
| N. A. Totolyan, V. M. Alifirova, K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. N. Zakharova, D. S. Kasatkin, S. V. Kotov, A. I. Nilov, S. A. Sivertseva, A. A. Sokolova, N. N. Spirin, F. A. Khabirov, D. Paradnika | ||
| "... active MS (HAMS), poses a number of difficult problems for specialists, including not only the choice ..." | ||
| Vol 12, No 1S (2020): Спецвыпуск: рассеянный склероз | Experience with cladribine tablets for highly active multiple sclerosis in everyday clinical practice | Abstract similar documents |
| S. V. Petrov, O. V. Boyko, A. N. Boyko | ||
| "... sclerosis (HAMS). After discussing the characteristics of action of the drug in clinical trials, the authors ..." | ||
| Vol 16, No 3 (2024) | Diffusion tensor tomography with tractography in assessment of the pyramidal system in patients with highly active multiple sclerosis | Abstract similar documents |
| A. N. Peshkin, G. T. Toniya, E. A. Stepanova, V. Yu. Lizhdvoi, S. V. Kotov | ||
| "... Objective: to study the pyramidal tract in patients with highly active multiple sclerosis (HAMS ..." | ||
| Vol 16, No 3 (2024) | Experience of cladribine tablets usage in the treatment of multiple sclerosis in the Multiple Sclerosis Centre of the Khanty-Mansi Autonomous Area — Yugra | Abstract similar documents |
| A. A. Sokolova, L. I. Anischenko, L. S. Zemlyanushin, E. A. Rubtsova | ||
| "... of treating patients with highly active MS (HAMS) with cladribine tablets in real-life clinical practice ..." | ||
| Vol 11, No 4 (2019) | New possibilities for the therapy of secondary progressive multiple sclerosis | Abstract similar documents |
| A. M. Petrov, E. V. Ivashkova, I. D. Stolyarov | ||
| "... in slowing the progression of disability in patients with SPMS in the international phase III (EXPAND ..." | ||
| Vol 4, No 2 (2012) | Clinical characteristics of multiple sclerosis in the Tomsk region | Abstract similar documents |
| V M Alifirova, M A Titova | ||
| "... moderate neurologic deficit and moderate disease progression. The women were observed to exhibit a more ..." | ||
| Vol 15 (2023): (Suppl. 1) | MicroRNAs as biomarkers of multiple sclerosis progression | Abstract similar documents |
| N. M. Baulina, I. S. Kiselev, O. G. Kulakova, E. V. Popova, O. O. Favorova, A. N. Boyko | ||
| "... of predicting and assessing disease progression with high sensitivity and specificity, which would be of great ..." | ||
| Vol 13, No 6 (2021) | Changes in retinal structures as markers of multiple sclerosis progression | Abstract similar documents |
| M. O. Poplyak, A. G. Trufanov, A. V. Temniy, D. S. Maltsev, O. B. Chakchir, A. V. Mikheev, D. I. Skulyabin, G. N. Bisaga, I. V. Litvinenko, M. M. Odinak | ||
| "... activity in patients with RMS and assessment of its progression in patients with SPMS. ..." | ||
| Vol 12, No 1 (2020) | Association of BAFF gene polymorphisms with multiple sclerosis progression | Abstract PDF (Eng) similar documents |
| I. V. Smagina, S. A. Elchaninova, A. S. Palashchenko | ||
| "... 1224141, rs9514827) with the progression rate and frequency of MS exacerbations. Patients and methods ..." | ||
| Vol 11, No 4 (2019) | Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects» | Abstract similar documents |
| N. V. Khachanova, A. N. Boyko, K. Z. Bakhtiyarova, Ya. V. Vlasov, E. P. Evdoshenko, S. A. Sivertseva, T. E. Schmidt, M. V. Shumilina | ||
| "... progression can be recorded, is stated to be 3 months. The exacerbation-unaffected disability progression ..." | ||
| Vol 15, No 2 (2023) | Rapidly progressive dementia with early onset associated with the I143T mutation in the PSEN1 gene: a clinical case in a family from Russia | Abstract similar documents |
| Yu. A. Shpilyukova, A. O. Protopopova, N. Yu. Abramycheva, E. Yu. Fedotova, S. N. Illarioshkin | ||
| "... of disorders. Some hereditary forms of Alzheimer's disease can also be aggressive, with onset at a young age ..." | ||
| Vol 6, No 2S (2014): Special issue "Stroke" | Intracranial atherosclerosis: Causes of ischemic stroke, diagnosis, and treatment | Abstract similar documents |
| V.A Sorokoumov, A.V. Savello | ||
| "... of aggressive medical prevention, primarily blood pressure reduction and different combinations of antiplatelet ..." | ||
| Vol 16, No 4 (2024) | Aviandr is a new original drug for treating anxiety | Abstract similar documents |
| V. A. Parfenov | ||
| "... the Hamilton Anxiety Scale (HAM-A), Hamilton Depression Scale (HAM-D) and Clinical Global Impression Scale (CGI ..." | ||
| Vol 15, No 3 (2023) | Patient with non-cardioembolic ischemic stroke or high-risk transient ischemic attack. Part 2. Secondary prophylaxis | Abstract similar documents |
| A. A. Kulesh, S. N. Yanishevsky, D. A. Demin, L. I. Syromyatnikova, O. I. Vinogradov | ||
| "... arch atheromatosis. This risk is also characteristic of patients with aggressive transient ischemic ..." | ||
| Vol 13, No 1 (2021) | The role of the new coronavirus infection (COVID-19) in the progression and development of cerebrovascular diseases. A competent choice of pathogenic treatment is the key to success in treatment and prevention. An expert’s view from the ‘red zone’ | Abstract similar documents |
| V. V. Kovalchuk | ||
| Vol 1, No 1 (2009) | THE ACUTE PERIOD OF ISCHEMIC STROKE: DIAGNOSIS AND TREATMENT | Abstract similar documents |
| V. A. Parfenov | ||
| "... stroke is stated to be based on the risk factors of its development, the rapid progression of focal ..." | ||
| Vol 8, No 2 (2016) | Treatment for mixed cognitive impairments and emotional disorders in young and middle-aged patients | Abstract similar documents |
| V. A. Parfenov, E. Yu. Solovyeva, L. M. Antonenko, A. B. Lokshina, T. Gorskaya | ||
| "... . Results. Tanakan® therapy resulted in health improvement, as shown by the HAM (Health, Activity, Mood ..." | ||
| Vol 5, No 4 (2013) | Clinical and neurological characteristics of patients with somatic referred back pain at the lumbosacral level | Abstract similar documents |
| Natalia Sergeevna Nikolaeva, A B Danilov | ||
| "... questionnaire. The health-activity-mood (HAM), SF-36, and Roland-Morris questionnaires were used to assess ..." | ||
| Vol 14, No 2 (2022) | Possibilities nootropic drugs in non-demented patients with vascular cognitive disorders | Abstract similar documents |
| M. N. Dadasheva, R. V. Gorenkov, V. A. Kruglov, K. N. Dadasheva, D. I. Lebedeva | ||
| "... Assessment (MoCA); 2) Hamilton Anxiety Rating Scale (HAM-A); 3) Subjective assessment of asthenia scale; 4 ..." | ||
| Vol 7, No 2 (2015) | Brain bioelectrical activity changes in patients with poststroke depression and apathy | Abstract similar documents |
| I. V. Kichuk, E. A. Petrova, N. A. Georgievskaya | ||
| "... (DSM-IV) criteria to diagnose depression and the Hamilton depression rating scale (HAM-D) and the mini ..." | ||
| Vol 16 (2024): (Suppl. 2) | Experience with the use of cladribine tablets in real-life clinical practice: independent analysis of data from 12 Russian clinical centres | Abstract similar documents |
| A. N. Boyko, V. M. Alifirova, D. V. Pashkovskaya, E. I. Kuchina, S. A. Sivertseva, E. L. Turova, Z. A. Goncharova, O. Yu. Rudenko, Yu. Yu. Pogrebnova, F. A. Khabirov, T. I. Khaibullin, N. N. Babicheva, N. L. Khoroshilova, O. V. Dzundza, O. A. Soldatova, A. N. Belova, G. Е. Sheiko, A. Е. Makarova, N. G. Glavinskaya | ||
| "... therapies such as natalizumab and ocrelizumab is noteworthy. Both drugs are prescribed for aggressive types ..." | ||
| Vol 16, No 5 (2024) | An Exploration of Locomotor Syndrome among Geriatric Population – A Narrative Review | Abstract PDF (Eng) similar documents |
| K. Shanmuganathan, S. Kalpana, J. S. Sundar, S. Valarmathi, G. Srinivas | ||
| "... to prevent and manage its progression, thereby improving the overall health and independence of geriatric ..." | ||
| Vol 13, No 1 (2021) | New possibilities of siponimod therapy in patients with secondary progressive multiple sclerosis | Abstract similar documents |
| D. S. Kasatkin, N. V. Khachanova, V. M. Alifirova, A. N. Boyko, K. Z. Bakhtiyarova, Ya. V. Vlasov, M. V. Davydovskaya, E. P. Evdoshenko, S. A. Sivertseva | ||
| "... during the transition to secondary progression. This paper reflects the opinion of the Council of Leading ..." | ||
| Vol 1, No 2 (2009) | METABOLIC CORRECTION OF NEUROLOGICAL COMPLICATIONS OF DIABETES MELLITUS | Abstract similar documents |
| S. A. Rumyantseva, V. A. Stupin, E. V. Silina, V. V. Mikhal'skiy, A. I. Perevedentsev, D. D. Ryzhova | ||
| "... and progression of neurological complications of diabetes mellitus are presented. The results of some ..." | ||
| Vol 16, No 6 (2024) | Management of patients with cognitive impairment in old age | Abstract similar documents |
| D. A. Grishina, A. B. Lokshina, E. A. Sokolov | ||
| "... progression. The possibilities of modern neuroprotective and symptomatic therapy of MCI and the role ..." | ||
| Vol 11, No 2 (2019) | Vascular factors in the genesis of dementia and the optimization of patient management | Abstract similar documents |
| O. D. Ostroumova, A. I. Kochetkov | ||
| "... at monitoring vascular risk factors, preventing stroke and progression of chronic cerebrovascular disease ..." | ||
| Vol 17, No 1 (2025) | Contribution of genomic variation to the severity of multiple sclerosis | Abstract similar documents |
| O. G. Kulakova, N. A. Matveeva, I. S. Kiselev, A. N. Boyko, O. O. Favorova | ||
| "... the genetic basis of MS progression may not only explain the nature of the observed clinical heterogeneity ..." | ||
| Vol 13, No 5 (2021) | Treatment of cognitive impairment in arterial hypertension | Abstract similar documents |
| Yu. A. Starchina, K. S. Sleptcova | ||
| "... therapy plays an essential role in preventing the development and slowing the progression of CI ..." | ||
| Vol 10, No 3 (2018) | Benign syringomyelia with the abortive type of the course | Abstract PDF (Eng) similar documents |
| E. G. Mendelevich, Ch. S. Nurullina | ||
| "... , lack of progression and/or development of myelopathic symptoms, and signs of syringomyelia cavity ..." | ||
| Vol 11, No 3S (2019): Спецвыпуск: когнитивные нарушения, цереброваскулярные заболевания | Vascular depression and cognitive dysfunction | Abstract similar documents |
| A. N. Bogolepova | ||
| "... , also has a negative impact on the course of cardiovascular disease, contributing to its progression ..." | ||
| Vol 11, No 2 (2019) | Pathogenesis, clinical features, and treatments of depression in Parkinson's disease | Abstract similar documents |
| I. V. Milyukhina | ||
| "... significantly affects the rate of disease progression and increases the risk of motor complications and dementia ..." | ||
| Vol 8, No 3 (2016) | Amyotrophic lateral sclerosis with extension of the central canal of the spinal cord according to magnetic resonance imaging data | Abstract similar documents |
| E. G. Mendelevich, G. R. Mukhamedzhanova, E. I. Bogdanov | ||
| "... are atypical for ALS, such as early age of onset, slow progression with long-term involvement of one leg ..." | ||
| Vol 9, No 2 (2017) | Chronic cerebral ischemia, neuroplasticity, possibilities of therapy | Abstract similar documents |
| E. I. Chukanova, A. S. Chukanova | ||
| "... , progression, and risk of exacerbations in patients with chronic cerebral ischemia. ..." | ||
| Vol 1, No 3-4 (2009) | COMPLEX THERAPY FOR HYPERTENSIVE AND MIXED ENCEPHALOPATHY | Abstract similar documents |
| S. A. Rumyantseva | ||
| "... Arterial hypertension (AH) is one of the main causes of the occurrence and progression of different ..." | ||
| Vol 5, No 4 (2013) | Cognitive impairments in epilepsy | Abstract similar documents |
| Aleksandr Anatolyevich Kostylev, N V Pizova, N A Pizov | ||
| "... the detection of new features in the course and progression of higher nervous system dysfunctions in epilepsy. ..." | ||
| Vol 4, No 2 (2012) | Artra is a model of combination symptom-modifying therapy for osteoarthrosis and intervertebral osteochondrosis | Abstract similar documents |
| V V Badokin | ||
| "... , but also to the slow progression, normalization, or stabilization of structural changes in the hyaline ..." | ||
| Vol 13, No 1S (2021): Спецвыпуск: рассеянный склероз | Influence of von Willebrand factor on common pathophysiological mechanisms of cerebrovascular diseases and multiple sclerosis | Abstract similar documents |
| I. A. Koltsov, M. Yu. Martynov, A. N. Yasamanova, I. A. Shchukin, M. S. Fidler, A. N. Boyko | ||
| "... to the development/progression of many diseases, including cerebrovascular disease and multiple sclerosis. Von ..." | ||
| Vol 13, No 5 (2021) | Paradoxial embolism as a cause of ischemic stroke in patient with sinus venosus atrial septal defect | Abstract PDF (Eng) similar documents |
| A. A. Kulesh, S. A. Mekhryakov, L. I. Syromyatnikova, N. H. Gorst, S. O. Drobakha, E. V. Nikolaeva | ||
| "... cerebral accidents and the progression of pulmonary hypertension, and the prevention of the development ..." | ||
| Vol 14, No 4 (2022) | Cognitive impairment in patients with coronavirus infection | Abstract similar documents |
| Y. A. Starchina, O. V. Kosivtsova | ||
| "... the clinical onset and progression of CI, including Alzheimer's disease. For the treatment of severe CI after ..." | ||
| Vol 13, No 1 (2021) | Chronic cerebral ischemia and headache in patients in primary care physician's practice | Abstract similar documents |
| V. N. Shishkova, T. V. Adasheva | ||
| "... of effective treatment, prevents the disease progression, and the development of strokes and dementia ..." | ||
| Vol 11, No 2S (2019): Спецвыпуск: боль в спине и конечностях | Facet joint osteoarthritis as a component of non-specific low back pain | Abstract similar documents |
| O. S. Davydov | ||
| "... complete pain relief in most cases and slows the progression of the disease. ..." | ||
| Vol 11, No 3 (2019) | Vascular cognitive impairment and Alzheimer's disease: Is there a relationship between them? | Abstract similar documents |
| G. R. Tabeeva, E. A. Kirjanova | ||
| "... on the clinical manifestation, severity, and rate of progression of CI. Alzheimer's disease (AD) and vascular CI ..." | ||
| Vol 9, No 4 (2017) | Hypertension and cognitive impairment: the standpoint of evidence-based medicine | Abstract similar documents |
| T. M. Ostroumova, V. A. Parfenov, O. D. Ostroumova | ||
| "... cognitive function and prevents the progression of CI and the development of dementia. The use ..." | ||
| Vol 9, No 2 (2017) | Cognitive impairment without dementia: A current view of the problem | Abstract similar documents |
| Yu. A. Starchina | ||
| "... allows the progression of CI to be curbed. The paper discusses the use of EGB761® in patients with CI. ..." | ||
| Vol 2, No 4 (2010) | Smoking and ischemic stroke | Abstract similar documents |
| D. V. Neverovskiy | ||
| "... . Smoking contributes to the progression of atherosclerosis, the elevation of blood pressure ..." | ||
| Vol 15, No 4 (2023) | The role of trimethylamine-N-oxide in the development of cerebrovascular disease (brief review) | Abstract similar documents |
| M. A. Kutlubaev, A. R. Rakhmatullin, R. F. Kutlubaeva | ||
| "... to the acceleration of atherosclerosis progression, platelet activation, and the development of aseptic inflammation ..." | ||
| Vol 16, No 3 (2024) | Psychotic disorders in Parkinson's disease: phenomenology, pathogenesis, therapeutic approaches (modern view on the problem) | Abstract similar documents |
| Kh. I. Alizade, A. A. Ragimova, E. Yu. Fedotova, S. N. Illarioshkin | ||
| "... . The development and progression of psychotic symptoms in patients with PD is due to a combination of exogenous ..." | ||
| Vol 13, No 3 (2021) | Severity and treatment of cognitive impairment | Abstract similar documents |
| Yu. A. Starchina, V. V. Zakharov | ||
| "... CI, which are more promising in terms of successful treatment and slowing down their progression. Age ..." | ||
| Vol 13, No 3 (2021) | Management tactics in patients with chronic cerebral ischemia during COVID-19 pandemic | Abstract PDF (Eng) similar documents |
| A. A. Kulesh | ||
| "... and arterioles. COVID-19 pandemic can modify CCI progression due to similar pathophysiology. In particular, COVID ..." | ||
| Vol 14, No 1 (2022) | COVID-19 associated multiple cranial neuropathies | Abstract similar documents |
| M. Yu. Maksimova, Ya. O. Grusha, E. I. Fettser | ||
| "... of the first symptoms or appear during the disease progression. Impairment of smell and taste is considered ..." | ||
| Vol 12, No 5 (2020) | Cognitive impairment, dizziness, and unsteadiness in hypertensive patients | Abstract similar documents |
| L. M. Antonenko, N. V. Vakhnina, D. O. Gromova | ||
| "... of vascular CI, selection of adequate therapy, and prevention of their further progression are of great ..." | ||
| Vol 13, No 1 (2021) | Cognitive impairment in hypertension | Abstract similar documents |
| Yu. A. Starchina, V. V. Zakharov | ||
| "... the development and slowing down the progression of CI through blood pressure control. Neurometabolic ..." | ||
| Vol 11, No 3S (2019): Спецвыпуск: когнитивные нарушения, цереброваскулярные заболевания | Intracranial hemorrhage in patients taking oral anticoagulants. Current possibilities for therapy | Abstract similar documents |
| S. N. Yanishevsky | ||
| "... disabilities is the progression rate of ICH, the possibility of using a specific antagonist can determine ..." | ||
| Vol 11, No 1 (2019) | Molecular mechanisms of myoprotective action of chondroitin sulfate and glucosamine sulfate in sarcopenia | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, A. M. Lila, N. A. Shostak, K. V. Rudakov | ||
| "... sarcopenia progression. ..." | ||
| Vol 11, No 4 (2019) | Poststroke cognitive impairment | Abstract similar documents |
| V. A. Parfenov | ||
| "... the progression of CI in stroke patients. The use of Actovegin in patients with CI after stroke is discussed ..." | ||
| Vol 8, No 2 (2016) | Psychogenic dizziness | Abstract similar documents |
| L. M. Antonenko | ||
| "... to the progression of psychogenic dizziness, to a considerable deterioration in quality of life, and to obvious ..." | ||
| Vol 10, No 2 (2018) | Current management tactics for patients with dementia | Abstract similar documents |
| A. V. Medvedeva, O. V. Kosivtsova, K. A. Makhinov | ||
| "... Dementia develops as a result of continuous long-term progression of less severe cognitive ..." | ||
| Vol 4, No 2 (2012) | Evolution of cognitive deficit: mild and moderate cognitive impairments | Abstract similar documents |
| V V Zakharov | ||
| "... the high risk of their progression. ..." | ||
| Vol 3, No 4 (2011) | Current therapy for cognitive impairments | Abstract similar documents |
| N. V. Vakhnina | ||
| "... and their degree. Measures to prevent CI progression and dementia: adequate treatment of existing cardiovascular ..." | ||
| Vol 16, No 2 (2024) | Diagnosis of Alzheimer's disease by using biological markers in posterior cortical atrophy | Abstract similar documents |
| D. A. Grishina, N. A. Khayalieva, V. V. Grinyuk, A. Yu. Tyurina | ||
| "... impairment and mild dementia is of practical importance, as anti-amyloid therapy can prevent the progression ..." | ||
| Vol 17, No 1 (2025) | Lower spastic paraplegia combined with hydromyelia | Abstract similar documents |
| E. G. Mendelevich, A. A. Kurbanova | ||
| "... and no progression according to the MRI data. The revision of the diagnosis and the clinical and genetic analysis ..." | ||
| Vol 6, No 4 (2014) | Nondrug therapy in the combination rehabilitation of patients with Parkinson’s disease | Abstract similar documents |
| V. L. Golubev, A. B. Kamakinova | ||
| "... wellbeing and little affects the course of the disease, without preventing its progression. Today ..." | ||
| Vol 13, No 5 (2021) | Evaluation and treatment of peripheral nervous system dysfunction in patients with prediabetes | Abstract similar documents |
| O. E. Zinovyeva, T. M. Ostroumova, M. V. Koniashova, N. A. Gorbachev | ||
| "... and/or progression of DN in patients with prediabetes, antioxidants are considered pathogenetic therapy. Alpha-lipoic ..." | ||
| 1 - 70 of 111 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
